136 related articles for article (PubMed ID: 36328157)
1. Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease.
Portman MA; Jacobs JP; Newburger JW; Berger F; Grosso MA; Duggal A; Tao B; Goldenberg NA;
J Am Coll Cardiol; 2022 Dec; 80(24):2301-2310. PubMed ID: 36328157
[TBL] [Abstract][Full Text] [Related]
2. ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism.
Bhatt MD; Portman MA; Berger F; Jacobs JP; Newburger J; Duggal A; Grosso M; Pandya G; Dave J; Goldenberg NA
Cardiol Young; 2021 Aug; 31(8):1213-1219. PubMed ID: 34344494
[TBL] [Abstract][Full Text] [Related]
3. Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease.
Payne RM; Burns KM; Glatz AC; Male C; Donti A; Brandão LR; Balling G; VanderPluym CJ; Bu'Lock F; Kochilas LK; Stiller B; Cnota JF; Rahkonen O; Khan A; Adorisio R; Stoica S; May L; Burns JC; Saraiva JFK; McHugh KE; Kim JS; Rubio A; Chía-Vazquez NG; Meador MR; Dyme JL; Reedy AM; Ajavon-Hartmann T; Jarugula P; Carlson-Taneja LE; Mills D; Wheaton O; Monagle P
J Am Coll Cardiol; 2023 Dec; 82(24):2296-2309. PubMed ID: 38057072
[TBL] [Abstract][Full Text] [Related]
4. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosis.
Sagiv E; Newland DM; Slee A; Olson AK; Portman MA
Cardiol Young; 2024 Apr; 34(4):870-875. PubMed ID: 37921220
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Halton J; Brandão LR; Luciani M; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Sharathkumar A; Svirin P; Gorbatikov K; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Reilly P; Brueckmann M; Albisetti M;
Lancet Haematol; 2021 Jan; 8(1):e22-e33. PubMed ID: 33290737
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
9. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
[TBL] [Abstract][Full Text] [Related]
10. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial.
Shim CY; Seo J; Kim YJ; Lee SH; De Caterina R; Lee S; Hong GR;
J Thorac Cardiovasc Surg; 2023 Jan; 165(1):58-67.e4. PubMed ID: 33726903
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
[TBL] [Abstract][Full Text] [Related]
13. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
[TBL] [Abstract][Full Text] [Related]
14. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M; Al-Saady N; Hjortshøj SP; Goudev A; Huber K; Cohen A; Jin J; Melino M; Winters SM; Goette A; Lip GYH
Clin Res Cardiol; 2020 Aug; 109(8):1018-1024. PubMed ID: 31915996
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
18. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
[TBL] [Abstract][Full Text] [Related]
19. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
20. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
Hirschl M; Kundi M
Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
